Spanish drug spending down by a fifth
This article was originally published in Scrip
Executive Summary
Spanish spending on pharmaceuticals is down yet again. Figures from the Spanish health ministry reveal a 20% drop in spending in August compared with the same month last year. More cost saving measures applicable from July, including increased patient co-payments and the removal of products from the reimbursement list, contributed significantly to the decline, says the ministry.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.